An interventional study of Vonoprazan and Esomeprazole 40mg in GERD, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Asian Institute of Gastroenterology, India · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 5th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 with no phase, and was the 12th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Tanta University · Sites in Egypt
Ages 17–60
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 414 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 118 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.
14 studies in Gastroesophageal Reflux by Asian Institute of Gastroenterology, India: 4 open now, 5 under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 14 studies in Gastroesophageal Reflux by Asian Institute of Gastroenterology, India, this one is one of 3 that started in 2025, is one of 8 with no phase, and was the 11th registered.
Asian Institute of Gastroenterology, India’s Gastroesophageal Reflux studies by the year they started, since 2015.
1 of the studies testing vonoprazan in Gastroesophageal Reflux that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, from their registry updates:
Among Asian Institute of Gastroenterology, India’s 14 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
Primary Objective
Secondary Objectives
Study Design:
The study will be open-label, but the outcome assessors will be blinded. Study Arms
Esomeprazole 40 mg once daily
Duration:
I
Study Procedures:
Baseline :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vonaprazon 10 mg heals gerd symptoms after 8 weeks
Drug: Vonoprazan
Vonaprazon 20 mg heals gerd symptoms after 8 weeks
Drug: Vonoprazan
Esomeprazole 40mg heals gerd symptoms after 8 weeks
Drug: Esomeprazole 40mg
Vonaprazon is potassium competitive acid blockers
Also known as: PCAB
esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
Also known as: Proton pump inhibitor
• Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).
healing of ulcers after taking vonaprazon 10mg, 20 mg
Time frame: 8 weeks
Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).
healing of ulcers after taking esomeprazole 40mg
Time frame: 8 weeks
• GERD-Q score improvement at 8 weeks (compared to baseline).
symtoms improvement like heartburn, regurgitation which can be calculated with scale 1 (mild symptoms ) to 5 (worse symptoms)
Time frame: 8 weeks
Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.
Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 11 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonoprazan · Esomeprazole
Asian Institute of Gastroenterology, India →